ATL313 Reduces Inflammation and Improves Survival in Sepsis Models
Author Information
Author(s): Christopher C. Moore, Edward N. Martin, Grace H. Lee, Tom Obrig, Joel Linden, W. Michael Scheld
Primary Institution: University of Virginia
Hypothesis
Can ATL313, an A2A adenosine receptor agonist, improve survival and reduce inflammation in murine sepsis models?
Conclusion
ATL313 significantly improves survival in mice with sepsis and reduces levels of pro-inflammatory cytokines.
Supporting Evidence
- ATL313 improved survival in mice infected with E. coli from 0% to 100%.
- Survival in mice treated with ATL313 and ceftriaxone was significantly higher than with ceftriaxone alone.
- ATL313 reduced levels of pro-inflammatory cytokines like TNF-α and increased IL-10.
Takeaway
This study shows that a drug called ATL313 can help mice survive sepsis by reducing inflammation in their bodies.
Methodology
Mice were treated with ATL313 or PBS after being infected with bacteria or LPS, and cytokine levels and survival were measured.
Limitations
Further studies are needed to confirm the clinical utility of ATL313 in humans.
Participant Demographics
Female C57BL/6 and BALB/c mice were used in the study.
Statistical Information
P-Value
p = 0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website